Skip to content
World Health Systems Facts

France: Wasteful Spending

France: Wasteful Spending

French Health System Overview
Health System Rankings
Health System Outcomes
Health System Coverage
Costs for Consumers
Health System Expenditures
French COVID-19 Policy

Health System Financing
Health System Personnel
Health System Physical Resources and Utilization
Long-Term Care
Health Information and Communications Technologies
Medical Training
Pharmaceuticals

Political System
Economic System
Population Demographics
People with Disabilities
Aging
Social Determinants & Health Equity
Health System History
Health System Challenges


Under Construction – Check Back Soon!


“Decreasing the benefit package is one means of decreasing the financial burden on SHI [Social Health Insurance]. Of all health care goods and services, drugs were the most affected by this type of measure. Between 1990 and 2009, prescription drug sales in France multiplied 2.5 times, with SHI covering approximately 75% of the total (Cour des comptes, 2011b). The steady increase in pharmaceutical expenditure has led to a series of measures aimed at limiting the usage of certain drugs and/or reducing the cost for SHI. Cost-containment measures have included increasing patient contributions (often covered by VHI), either by de-listing the drugs completely or reducing the rate of SHI coverage, reducing drug prices and encouraging generic substitution. Economic evaluation is the newest tool in the cost-containment policies.

“De-listing drugs has proven to be politically sensitive, as revealed by the history of de-listing since the late 1990s. In certain cases, drugs with insufficient SMR were subject to lower prices or reimbursement rates or even left at a 65% rate rather than being de-listed. A provisional coverage rate of 15% was instituted for certain drugs as an interim step towards de-listing in 2008. In 2010, the coverage rate for drugs with weak relative SMR decreased from 35% to 15%, and in 2011, the rate for drugs with moderate SMR was reduced from 35% to 30%. An additional 26 drugs were de-listed in 2011, including 17 that had been covered at 15%. The Minister in charge of Health announced in January 2011 that all drugs with an insufficient SMR would be de-listed or subject to a systematically motivated decision if coverage was to be maintained. However, to date there has been no decree authorizing this alternative coverage procedure, and the left-wing government elected in 2012 has not put this measure forward since then.”

Source: Chevreul K, Berg Brigham K, Durand-Zaleski I, Hernández-Quevedo C. France: Health system review. Health Systems in Transition, 2015; 17(3): 1–218.


“Strict control of tariffs was applied, notably to the price of drugs but also to other type of service such hospital remuneration, medical devices and professional tariffs. As a result of tight control of doctors’ tariffs, extra-billing, which is not covered by SHI, was permitted starting in the 1980s for certain categories of doctor (see Sector 2 doctors; section 3.7.2). However, extra-billing in some specialties has significantly increased OOP payments, thereby impairing access in some areas where extra-billing is the rule (e.g. gynaecologists in Paris). For this reason, policies to reduce extra-billing were developed starting in 2013.”

Source: Chevreul K, Berg Brigham K, Durand-Zaleski I, Hernández-Quevedo C. France: Health system review. Health Systems in Transition, 2015; 17(3): 1–218.


“Extra-billing is permitted for doctors practising in Sector 2, which includes 42% of specialists and 11% of GPs. In an effort to discourage excessive extra-billing, a “carrot and stick” approach was taken in a 2012 amendment to the collective bargaining agreement between SHI and physician unions. Since 2013, Sector 2 doctors may be subject to sanctions for excessive extra-billing, defined as fees in excess of 150% of official SHI tariffs. In addition, a voluntary three-year “Access to Health Care” contract (contrat d’accès aux soins) provides Sector 2 doctors with incentives to freeze their fees and average rate of excess billing at 2012 levels and to perform a share of their services at statutory tariff levels. The incentives include social and fiscal advantages and access for Sector 2 specialists to the €2 higher statutory tariffs of Sector 1 doctors. Patients consulting doctors who have signed the agreement also benefit from improved coverage of the services by SHI. However, from April 2015, patients of non-signatory doctors may be exposed to increased OOP costs under a decree that places a ceiling on the amount of extra-billing that may be covered by VHI contracts (125% of official SHI tariffs in 2015–2016 and 100% thereafter).

“The average rate of extra-billing by doctors practising in Sector 2 decreased from 56.9% in 2011 to 56.3% in 2013, marking the end of nearly uninterrupted increases in extra-billing since the 1980s. One explanation is fear of sanctions for excessive extra-billing. The financial crisis may also been a contributing factor, as doctors responded to the reduced purchasing power of their patients.”

Source: Chevreul K, Berg Brigham K, Durand-Zaleski I, Hernández-Quevedo C. France: Health system review. Health Systems in Transition, 2015; 17(3): 1–218.


Health Systems Facts is a project of the Real Reporting Foundation. We provide reliable statistics and other data from authoritative sources regarding health systems in the US and sixteen other nations.


Page last updated Feb. 2, 2023 by Doug McVay, Editor.

  • Home
  • About Health Systems Facts
    • Contact Us
    • Join Our Email List
  • Breaking News & Opinion
  • Upcoming Events
  • Seventeen National Health Systems
    • Austria
    • Canada
    • Costa Rica
    • Czech Republic
    • Denmark
    • France
    • Germany
    • Hungary
    • Italy
    • Japan
    • Netherlands
    • South Korea
    • Spain
    • Sweden
    • Switzerland
    • United Kingdom
    • United States
  • Comparing National Health Systems
    • Healthcare Access and Quality Index
    • Sustainable Development Goals Health Index
    • Mirror Mirror 2021
    • World Health Report 2000
    • International Health Systems In Perspective
    • Lessons for US Health Reform
  • Aging
  • Health System Outcomes
  • Healthcare Spending
  • Healthcare Workers
    • Health System Personnel
    • Health Workforce Training
  • Information and Communications Technologies
  • Long-Term Services and Supports
  • People With Disabilities
  • Pharmaceutical Pricing and Regulation
  • Social Determinants & Health Equity
  • Wasteful Spending
  • Various US Health System Proposals
    • Affordable Care Act
    • All Payer
    • Public Option
    • Single Payer / “Medicare For All”
    • Universal Health Coverage
  • Recommended Resources
  • Privacy Policy
    • Cookie Policy
  • Facebook
  • LinkedIn
  • Twitter

© 2019-2022 Real Reporting Foundation | Theme by WordPress Theme Detector

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
_GRECAPTCHA5 months 27 daysThis cookie is set by Google. In addition to certain standard Google cookies, reCAPTCHA sets a necessary cookie (_GRECAPTCHA) when executed for the purpose of providing its risk analysis.
cookielawinfo-checkbox-advertisement1 yearThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertisement".
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThis cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. The cookies store information anonymously and assign a randomly generated number to identify unique visitors.
_gat_UA-71314304-21 minuteThis is a pattern type cookie set by Google Analytics, where the pattern element on the name contains the unique identity number of the account or website it relates to. It appears to be a variation of the _gat cookie which is used to limit the amount of data recorded by Google on high traffic volume websites.
_gcl_au3 monthsThis cookie is used by Google Analytics to understand user interaction with the website.
_gid1 dayThis cookie is installed by Google Analytics. The cookie is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visted in an anonymous form.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
CookieDurationDescription
IDE1 year 24 daysUsed by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
test_cookie15 minutesThis cookie is set by doubleclick.net. The purpose of the cookie is to determine if the user's browser supports cookies.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT
Powered by CookieYes Logo